Losartan attenuates bleomycin-induced pulmonary fibrosis in rats

Respiration

Volumn 73, Issue 2, 2006, Pages 236-242

  Hong, Wei Yao ^a   Jian, Ping Zhu ^a   Meng, Hui Zhao ^a   Lu, Yuan ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bleomycin; Losartan; Malondialdehyde; Pulmonary fibrosis; Superoxide dismutase; TGF 1

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BLEOMYCIN; HYDROXYPROLINE; LOSARTAN; MALONALDEHYDE; PREDNISONE; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HISTOLOGY; INFLAMMATORY CELL; LUNG FIBROSIS; LUNG HOMOGENATE; LUNG PARENCHYMA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SPECTROSCOPY; STAINING;

EID: 33645216539     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090140     Document Type: Article

References (26)

1. Kroegel C, Mock B, Hengst U, Reissig A: Interferon-gamma-1b: therapeutic option in advanced idiopathic pulmonary fibrosis? Respiration 2004;71:656-657.
2. Song L, Wang D, Cui X, Shi Z, Yang H: Kinetic alterations of angiotensin-II and nitric oxide in radiation pulmonary fibrosis. J Environ Pathol Toxicol Oncol 1998;17:141-150.
3. Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S: Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 2004;59:31-38.
4. Li X, Rayford H, Uhal BD: Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am J Pathol 2003;163:2523-2530.
5. Marshall RP, McAnulty RJ, Laurent GJ: Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med 2000;161:1999-2004.
6. Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD: Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2000;279:L143-L151.
7. Molteni A, Moulder JE, Cohen EF, Ward WF, Fish BL, Taylor JM, Wolfe LF, Brizio-Molteni L, Veno P: Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 2000;76:523-532.
8. Borzone G, Moreno R, Urrea R, Meneses M, Oyarzun M, Lisboa C: Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;163:1648-1653.
9. Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW, Crystal RG: Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis 1979;120:893-899.
10. Keogh KA, Standing J, Kane GC, Terzic A, Limper AH: Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice. Eur Respir J 2005;25:708-714.
11. Marshall RP, Gohlke P, Chambers RC, Howell DC, Bottoms SE, Unger T, McAnulty RJ, Laurent GJ: Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004;286:L156-L164.
12. Hagiwara SI, Ishii Y, Kitamura S: Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med 2000;162:225-231.
13. Friedman SL: The answer: angiotensin II. The question: What do inflammation, oxidant stress and fibrogenesis have in common? J Hepatol 2004;40:1050-1052.
14. Anjaneyulu M, Chopra K: Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney. Am J Nephrol 2004;24:488-496.
15. Gatsura SV, Zinchuk VV: Effect of enalapril maleate and losartan on the size of experimental myocardial infarction, hemoglobin affinity to oxygen and various parameters of lipid peroxidation (in Russian). Eksp Klin Farmakol 2004;67:19-21.
16. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS: Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003;285:R117-R124.
17. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 2001;38:635-638.
18. Sun Y, Zhang J, Lu L, Bedigian MP, Robinson AD, Weber KT: Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med 2004;143:41-51.
19. Siegert A, Ritz E, Orth S, Wagner J: Differential regulation of transforming growth factor receptors by angiotensin II and transforming growth factor-β1 in vascular smooth muscle. J Mol Med 1999;77:437-445.
20. Yao HW, Li J, Chen JQ: Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CC14 in rats. Dig Dis Sci 2004;49:1589-1594.
21. Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ: Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 2004;126:438-446.
22. Burrell LM, Johnston CI, Tikellis C, Cooper ME: ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 2004;15:166-169.
23. Morrissey JJ, Klahr S: Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol 1999;276:F39-F45.
24. Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, Matsuura H, Chayama K, Teranishi Y, Iba O, Amano K, Matsubara H: Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 2003;41:99-107.
25. Selman M, Pardo A: The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29:S93-S97.
26. Selman M, King TE, Pardo A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151.